NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Lantern Pharma Inc (NASDAQ: LTRN)
LTRN Technical Analysis
4
As on 9th Jun 2023 LTRN STOCK Price closed @ 5.40 and we RECOMMEND Sell for LONG-TERM with Stoploss of 5.88 & Strong Sell for SHORT-TERM with Stoploss of 6.81 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LTRNSTOCK Price
Open | 5.59 | Change | Price | % |
High | 5.60 | 1 Day | -0.09 | -1.64 |
Low | 5.35 | 1 Week | 0.56 | 11.57 |
Close | 5.40 | 1 Month | 0.84 | 18.42 |
Volume | 31000 | 1 Year | -2.29 | -29.78 |
52 Week High 8.22 | 52 Week Low 4.19 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
LTRN Daily Charts |
LTRN Intraday Charts |
Whats New @ Bazaartrend |
LTRN Free Analysis |
|
LTRN Important Levels Intraday
RESISTANCE | 5.88 |
RESISTANCE | 5.73 |
RESISTANCE | 5.63 |
RESISTANCE | 5.54 |
SUPPORT | 5.26 |
SUPPORT | 5.17 |
SUPPORT | 5.07 |
SUPPORT | 4.92 |
LTRN Forecast May 2024
4th UP Forecast | 10.89 |
3rd UP Forecast | 9.13 |
2nd UP Forecast | 8.04 |
1st UP Forecast | 6.95 |
1st DOWN Forecast | 3.85 |
2nd DOWN Forecast | 2.76 |
3rd DOWN Forecast | 1.67 |
4th DOWN Forecast | -0.09 |
LTRN Weekly Forecast
4th UP Forecast | 7.35 |
3rd UP Forecast | 6.72 |
2nd UP Forecast | 6.34 |
1st UP Forecast | 5.95 |
1st DOWN Forecast | 4.85 |
2nd DOWN Forecast | 4.46 |
3rd DOWN Forecast | 4.08 |
4th DOWN Forecast | 3.45 |
LTRN Forecast2024
4th UP Forecast | 13.59 |
3rd UP Forecast | 10.96 |
2nd UP Forecast | 9.34 |
1st UP Forecast | 7.72 |
1st DOWN Forecast | 3.08 |
2nd DOWN Forecast | 1.46 |
3rd DOWN Forecast | -0.16 |
4th DOWN Forecast | -2.79 |
Lantern Pharma Inc ( NASDAQ USA Symbol : LTRN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LTRN Other Details
Segment | EQ | |
Market Capital | 115642560.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
LTRN Address
LTRN Latest News
LTRN Business Profile
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service